NuVasive Gains FDA Clearance for Thoracolumbar Interbodies

NuVasive received FDA 510(k) clearance for its thoracolumbar interbody portfolio to include the treatment of multi-level sagittal deformities in the thoracolumbar spine. This clearance expands the portfolio's indications from one- to two-level spine surgery, to now multiple levels.

NuVasive's thoracolumbar portfolio of static and...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us